# Cyrus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cyrus-therapeutics

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.cyrustx.com
- Total disclosed funding: $11M
- Latest round: Series B (Jan 27, 2022)
- Investors on record: 7

## About

Based in Seoul, South Korea, and founded in 2019 by Byong-Moon Kim (CEO), Cyrus Therapeutics, Inc. operates as a biotechnology company specializing in developing a new anticancer drug for a resistance-causing target. In January 2022, Cyrus Therapeutics, Inc. raised KRW 29 billion in series C funding from Kolon Investment, Paratus Investment, Timefolio Asset Management, Atinum Investment, etc. 

Cyrus Therapeutics, Inc. provides medicine developers focusing on chronic or life-threatening diseases with high unmet needs. Furthermore, the company's technology employs a variety of new drug modalities, including traditional small molecule inhibitors and the primary focus is on developing small molecule medicines to conquer unsolvable cancer targets, as well as expanding new chemical spaces such as targeted protein degraders (TPDs) and antibody recruiting molecules (ARMs).

The investment which was held on January 2022, plans to help Cyrus Therapeutics, Inc. in its pipeline development-related clinical trials and secure additional pre-clinical tasks by next year.

## Funding rounds

- Series B, Jan 27, 2022, $2.4M — Atinum Investment, Mirae Asset Capital, Timefolio Asset Management, Kolon Investment, Mirae Asset Venture Investment, Paratus Investment, Green Cross LabCell Corporation
- Series A, Sep 27, 2020, $8.6M — Timefolio Asset Management, Kolon Investment, Paratus Investment

## Investors

- Timefolio Asset Management — Series A, Series B
- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series A, Series B
- Paratus Investment (https://capitalatlas.ai/funds/paratus-investment) — Series A, Series B
- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series B
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series B
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series B
- Green Cross LabCell Corporation — Series B